A study to test different doses of BI 3923948 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors)
1538-0001
Phase 1 other active
Quick answer
A study to test different doses of BI 3923948 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors) for advanced, unresectable and/or metastatic solid tumors is a Phase 1 program (other) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim International GmbH
- Indication
- advanced, unresectable and/or metastatic solid tumors
- Phase
- Phase 1
- Modality
- other
- Status
- active